Figure 1

Human MSLN E1 murine

Human MSLN E2 murine

Human MSLN E3 murine

Human MSLN E4 murine

Human MSLN E6 murine

Human MSLN E6 murine

fully human MSLN

Figure 2a


CHO hu MSLN
HPB-ALL hu CD3+
CHO mac MSLN
LnPx4119 mac CD3+
OVCAR-8 end. MSLN
MS 1 x I2C-HALB
MS 2 x I2C-HALB
MS 3 x I2C-HALB
MS 4 x I2C-HALB

Figure 2b


CHO hu MSLN
HPB-ALL hu CD3+
CHO mac MSLN
LnPx4119 mac CD3+
OVCAR-8 end. MSLN
MS 5 x I2C-HALB
MS 6 x I2C-HALB
MS 7 x I2C-HALB
MS 8 x I2C-HALB

Figure 3a


CHO MSLN V2*
CHO MSLN V6*
CHO mac MSLN-L
Non-transfected CHO
MS 1 x I2C-HALB
MS 2 x I2C-HALB
MS 3x I2C-HALB
MS 4 x I2C-HALB
Positive Control

Figure 3b


CHO MSLN V2*
CHO MSLN V6*
CHO mac MSLN-L
Non-transfected CHO
MS 5 x I2C-HALB
MS 6 x I2C-HALB
MS 7 x I2C-HALB
MS 8 x I2C-HALB

Figure 4



Figure 5



Figure 6


MS 3 x I2C-HALB
MS 3 x I2C-HALB +50ng/ml sMSLN
MS 3 x I2C-HALB +400ng/ml sMSLN
MS 4 x I2C-HALB
MS 4 x I2C-HALB +50ng/ml sMSLN
MS 4 x I2C-HALB +400ng/ml sMSLN
MS 5 x I2C-HALB
MS 5 x I2C-HALB +50ng/ml sMSLN
MS 5 x I2C-HALB +400ng/ml sMSLN
Lysis (%)
BiTE Conc. [pg/ml]

Figure 8



Figure 7



Figure 9



Figure 10



Figure 11


MS 4 x I2C-HALB
70.69
70.37
MS 2 x I2C-HALB
69.21
70.75
77.75
Blue Line = OD280 nm
Red Line = OD254 nm

Figure 12


MS 4 x I2C-HALB
MS 6 x I2C-HALB
Blue Line = OD280 nm
Red Line = OD254 nm

Figure 13



Figure 14



Figure 15



Figure 16



Figure 17



Figure 19



Figure 18


HLE-BiTE® serum concentration [nmol], dose normalized to 15 µg/kg
10
1
0.1
0.01
0.001
0
56
112
168
224
280
336
Time [h]
Compound 2b
Compound 2a


HLE-BiTE® serum concentration [nmol], dose normalized to 15 µg/kg
10
1
0.1
0.01
0.001
0
56
112
168
224
280
336
Time [h]
Compound 5b
Compound 5a


HLE-BiTE® serum concentration [nmol], dose normalized to 15 µg/kg
10
1
0.1
0.01
0.001
0
56
112
168
224
280
336
Time [h]
Compound 1b
Compound 1a


HLE-BiTE® serum concentration [nmol], dose normalized to 15 µg/kg
10
1
0.1
0.01
0.001
0
56
112
168
224
280
336
Time [h]
Compound 3b
Compound 3a